Molecular therapy for Bone disorders: LRRC4/NGL-2 (Leucine rich repeat containing 4/Netrin-G ligand-2) inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 6/February/2017, 10.34 pm

Anticancer therapy: MiRNA-9600 increases the expression of tumor suppressor PTPN14 (Pez), inhibits proliferation, and promotes apoptosis of cancer cells via down regulation of its target gene, 6/February/2017, 10.19 pm
February 6, 2017
Natural product-based Lifespan extension therapy: Kaemphferol, found in Aloe Vera, among others, prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 6/February/2017, 10.48 pm
February 6, 2017
Show all

Introduction: What they say

A study from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA has reported that “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.”

This study was published in the June 25, 2014 Nature  [I.F >42] by Prof. Wan Y, Krzeszinski and others from  the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.


What we say:

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: LRRC4/NGL-2 (Leucine rich repeat containing 4/Netrin-G ligand-2) inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene


From Research findings to Therapeutic utility

LRRC4/NGL-2, by up-regulating its target gene, it may suppress the expression of Tgif2. Thereby, it may inhibit the progression of Osteoporosis and bone metastasis. 

price-50[easy_payment currency=”USD”]

Thus, pharmacological formulations encompassing “LRRC4/NGL-2 activators or LRRC4/NGL-2 activator plus any of the known compounds that are in use to treat osteoporosis” can be used to inhibit osteoporosis and bone metastasis.


Details of the research findings: 

Idea Formulated (with experimental evidence) by: Dr L Boominathan PhD

Undisclosed mechanistic information: How LRRC4/NGL-2 suppresses the expression of Tgif2

Amount: $50#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

#Research cooperation

For purchase & payment details, you may reach us at admin@genomediscovery.org


 References:

CitationBoominathan, L., Molecular therapy for Bone disorders: LRRC4/NGL-2 (Leucine rich repeat containing 4/Netrin-G ligand-2) inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 6/February/2017, 10.34 pm., Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com/

Comments are closed.